P5403The impact of inflammation on the outcome of cardiac amyloidosis

Conclusions: Patients taking tafamidis experienced few adverse effects, however a significant proportion of patients showed progression of the disease during this long follow-up.Conduction abnormalities continued to evolve, as well as surrogate markers of heart failure, even though this was rarer in this early-onset Val30Met cohort.More studies regarding long-term effects of tafamidis and comparison with other treatment options are needed.